Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16044963rdf:typepubmed:Citationlld:pubmed
pubmed-article:16044963lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C0854750lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:16044963lifeskim:mentionsumls-concept:C0701185lld:lifeskim
pubmed-article:16044963pubmed:issue7lld:pubmed
pubmed-article:16044963pubmed:dateCreated2005-7-27lld:pubmed
pubmed-article:16044963pubmed:abstractTextSecond-line chemotherapy with bi-weekly CPT-11 and cisplatin (CDDP) was given to 19 patients with recurrent colorectal cancer resistant to 5-FU based chemotherapy. The 19 patients consisted of 18 men and 1 woman with a mean age of 61.3 years. Nine patients had liver metastasis, 4 had lung metastasis, 2 had local recurrence, 2 had both local recurrence and lung metastasis, respectively, 1 had local metastasis and lymph node metastasis, and 1 had bone metastasis. CPT-11 (80 mg/m2) and CDDP (30 mg/m2) were administered bi-weekly. The objective overall response rate was 15.8%. The time to progression was 146 days, and the median survival time was 477 days. Grade 3 leucopenia and nausea occurred in 1 patient (5.3%). CPT-11 and CDDP treatment should be considered as second-line chemotherapy for colorectal cancer resistant to 5-FU based chemotherapy.lld:pubmed
pubmed-article:16044963pubmed:languagejpnlld:pubmed
pubmed-article:16044963pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16044963pubmed:citationSubsetIMlld:pubmed
pubmed-article:16044963pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16044963pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16044963pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16044963pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16044963pubmed:statusMEDLINElld:pubmed
pubmed-article:16044963pubmed:monthJullld:pubmed
pubmed-article:16044963pubmed:issn0385-0684lld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:SuzukiMamoruMlld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:TanakaSeiichi...lld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:HaradaNobuhik...lld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:SuzukiShujiSlld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:TakeoYasuyosh...lld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:HayashiTsuneo...lld:pubmed
pubmed-article:16044963pubmed:authorpubmed-author:HanyuFujioFlld:pubmed
pubmed-article:16044963pubmed:issnTypePrintlld:pubmed
pubmed-article:16044963pubmed:volume32lld:pubmed
pubmed-article:16044963pubmed:ownerNLMlld:pubmed
pubmed-article:16044963pubmed:authorsCompleteYlld:pubmed
pubmed-article:16044963pubmed:pagination1007-10lld:pubmed
pubmed-article:16044963pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:meshHeadingpubmed-meshheading:16044963...lld:pubmed
pubmed-article:16044963pubmed:year2005lld:pubmed
pubmed-article:16044963pubmed:articleTitle[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].lld:pubmed
pubmed-article:16044963pubmed:affiliationHachioji Digestive Disease Hospital.lld:pubmed
pubmed-article:16044963pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16044963pubmed:publicationTypeEnglish Abstractlld:pubmed